The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study

6533b827fe1ef96bd128703b

RESEARCH PRODUCT

The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study

Francesco Dieli Patrizia Dorangricchia Giuseppe Cicero Rossella De Luca

subject

Male 0301 basic medicine Oncology Cancer Research medicine.medical_treatment Docetaxel Kaplan-Meier Estimate urologic and male genital diseases Drug resistant Antineoplastic Agent chemistry.chemical_compound Prostate cancer 0302 clinical medicine Prednisone Clinical endpoint Prospective Studies Neoplasm Metastasis Prospective cohort study Aged 80 and over Prostate cancer General Medicine Middle Aged Neoplasm Metastasi Prostatic Neoplasms Castration-Resistant Prostate-specific antigen Treatment Outcome Oncology Docetaxel 030220 oncology & carcinogenesis Benzamides Regression Analysis Taxoids Human medicine.drug medicine.medical_specialty Antineoplastic Agents Adenocarcinoma Regression Analysi 03 medical and health sciences Taxoid Internal medicine Nitriles Phenylthiohydantoin Enzalutamide medicine Chemotherapy Humans Enzalutamide Aged Chemotherapy business.industry Prostatic Neoplasms Prostate-Specific Antigen medicine.disease Prospective Studie 030104 developmental biology chemistry Drug Resistance Neoplasm Prostatic Neoplasm Prednisone business

description

Background/Aim: To evaluate the effectiveness of enzalutamide in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer, progressing after chemotherapy with docetaxel plus prednisone. Patients and Methods: A total of 60 patients were enrolled. Reduction in serum prostate-specific antigen (PSA) was assessed as the primary endpoint, while reduction in pain, safety, progression-free survival and overall survival represented secondary endpoints. Results: Enzalutamide was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum levels of PSA before and after treatment was observed. A significant correlation between PSA response and overall survival was also noted. The regression analysis revealed PSA level to be predictive of overall survival. Conclusion: Enzalutamide was shown to be an effective and welltolerated therapeutic option in patients with metastatic castration-resistant prostate cancer progressing after docetaxel plus prednisone treatment.

year	journal	country	edition	language
2017-03-17	Anticancer Research

https://doi.org/10.21873/anticanres.11472